国产成人精品一区二区激情-国产久久热这里只有精品-国产一级黄色片在线观看-自拍一区在线视频观看

咨詢熱線

15000266580

當(dāng)前位置:首頁 >產(chǎn)品中心>細(xì)胞庫>人腫瘤細(xì)胞、癌細(xì)胞>U-937人組織細(xì)胞淋巴瘤細(xì)胞

人組織細(xì)胞淋巴瘤細(xì)胞

簡要描述:CRL-1593.2 U-937 人組織細(xì)胞淋巴瘤細(xì)胞,
原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種;
細(xì)胞庫管理規(guī)范,提供的細(xì)胞株背景清楚,
提供參考文獻(xiàn)和培養(yǎng)條件!

  • 產(chǎn)品型號(hào):U-937
  • 廠商性質(zhì):生產(chǎn)廠家
  • 更新時(shí)間:2024-11-12
  • 訪  問  量:1830

產(chǎn)品分類

Product Category

詳細(xì)介紹

CRL-1593.2 U-937 人組織細(xì)胞淋巴瘤細(xì)胞

ATCC® Number: CRL-1593.2™ Price:

Designations: U-937

Depositors: H Koren

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Homo sapiens (human)

Morphology: monocyte

CRL-1593.2 U-937 人組織細(xì)胞淋巴瘤細(xì)胞

Source: Disease: histiocytic lymphoma

Cellular Products: lysozyme; beta-2-microglobulin (beta 2 microglobulin); tumor necrosis factor (TNF), also known as tumor necrosis factor alpha (TNF-alpha, TNF alpha), after stimulation with phorbol myristic acid (PMA)

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.


Restrictions: The original U-937 cell line was established by Dr. K. Nilsson's laboratory in 1974 and he has requested the following: (1) In all papers reporting any use of this cell line or any derivatives thereof a direct reference should be made to Sundstrom and Nilsson (Int. J. Cancer 17: 565-577, 1976). (2) Any proposed commercial use of the cells should be negotiated with Professor Kenneth Nilsson, Rudbeck Laboratory, SE-751 85 Uppsala, Sweden. (3) No distribution of any of the cells or sublines derived therefrom should be made to third parties; (4) The cells should be used for non-clinical, non-commercial research only.

Isolation: Isolation date: 1974

Applications: transfection host (Roche FuGENE® Transfection Reagents

Nucleofection technology from Lonza)

Receptors: complement (C3)

DNA Profile (STR): Amelogenin: X

CSF1PO: 12

D13S317: 10,12

D16S539: 12

D5S818: 12

D7S820: 9,11

THO1: 9.3

TPOX: 8,11

vWA: 15

Age: 37 years

Gender: male

Ethnicity: Caucasian

Comments: The U-937 cell line was derived by Sundstrom and Nilsson in 1974 from malignant cells obtained from the pleural effusion of a patient with histiocytic lymphoma.

Studies since 1979 have shown that U-937 cells can be induced to terminal monocytic differentiation by supernatants from human mixed lymphocyte cultures,

phorbol esters, vitamin D3, gamma interferon, tumor necrosis factor (TNF) and, retinoic acid.

The cells are negative for immunoglobulin production and Epstein-Barr virus expression.

The cells express the Fas antigen, and are sensitive to TNF and anti-Fas antibodies.

In 1994, PCR and cytogenetic analyses showed that a number of stocks of U-937 were contaminated with the human myeloid leukemia cell line, K-562.

In the earliest stocks available, the level of contamination was 0.6%. [40484]

Distribution was discontinued in March 1994, except if required for patent purposes.

Anyone who wishes to receive a sample of this original material should contact the Head of the ATCC Patent Depository.

A stock of CRL-1593 found to be free of K-562 was propagated continuously for 8 weeks and tested weekly by PCR.

Distribution and seed stocks give DNA profiles characteristic of U-937 only.

Such preparations are now offered as authentic U-937 (ATCC CRL-1593.2) and are believed to be free of second subpopulations.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Temperature: 37.0°C

Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml.

Interval: Maintain cell density between 1 X 10(5) and 2 X 10(6) viable cells/ml.

Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density)

Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO

Storage temperature: liquid nitrogen vapor phase

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

References: 1080: Ralph P, et al. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J. Exp. Med. 143: 1528-1533, 1976. PubMed: 1083890

21866: . Gene expression during normal and malignant differentiation. London: Academic Press; 1985.

21876: . International symposium on new trends in human immunology and cancer immunotherapy. Paris: Doin Editeurs; 1980.

22906: Koren HS, et al. In vitro activation of a human macrophage-like cell line. Nature 279: 328-331, 1979. PubMed: 450085

22912: Gidlund M, et al. Natural killer cells kill tumour cells at a given stage of differentiation. Nature 292: 848-850, 1981. PubMed: 7266653

23049: Olsson I, et al. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol. Cancer Res. 43: 5862-5867, 1983. PubMed: 6315218

23103: Morimoto H, et al. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 53: 2591-2596, 1993. PubMed: 7684321




CRL-1593.2 U-937



















產(chǎn)品咨詢

留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細(xì)地址:

  • 補(bǔ)充說明:

  • 驗(yàn)證碼:

    請(qǐng)輸入計(jì)算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7
聯(lián)系方式

郵箱:xiangfbio@163.com

地址:上海市虹口區(qū)四平路710號(hào)7層

咨詢熱線

400-821-8510

(周一至周日9:00- 19:00)

在線咨詢
  • 掃一掃 微信咨詢

Copyright©2024 上海復(fù)祥生物科技有限公司 All Right Reserved    備案號(hào):滬ICP備10013034號(hào)-2     sitemap.xml
技術(shù)支持:化工儀器網(wǎng)    管理登陸
岫岩| 增城市| 淮阳县| 微山县| 长阳| 河东区| 泸西县| 治县。| 东方市| 涞源县| 五原县| 丹寨县| 上饶市| 武义县| 汾西县| 沂南县| 文昌市| 江华| 马关县| 涞水县| 将乐县| 巴彦淖尔市| 石狮市| 巍山| 开封市| 谷城县| 崇礼县| 扬中市| 察雅县| 宁国市| 阿拉善右旗| 内江市| 兰溪市| 盐边县| 吴旗县| 绵竹市| 开远市| 普格县| 喀喇| 博罗县| 江川县|